Who are Sofosbuvir and Daklatasuvir's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sofosbuvir-and-daklatasuvir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sofosbuvir and Daklatasuvir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sofosbuvir and Daklatasuvir (Sofosbuvir and Daklatasuvir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor. Area: Infectious Disease.

phase 3 NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor HCV NS5B RNA-dependent RNA polymerase and HCV NS5A protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Sofosbuvir and Daklatasuvir (Sofosbuvir and Daklatasuvir) — Sherief Abd-Elsalam. Sofosbuvir and Daklatasuvir work together to inhibit the HCV NS5B RNA-dependent RNA polymerase and NS5A protein, respectively, to treat hepatitis C virus infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sofosbuvir and Daklatasuvir TARGET	Sofosbuvir and Daklatasuvir	Sherief Abd-Elsalam	phase 3	NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor	HCV NS5B RNA-dependent RNA polymerase and HCV NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor class)

Sherief Abd-Elsalam · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sofosbuvir and Daklatasuvir — Competitive Intelligence Brief. https://druglandscape.com/ci/sofosbuvir-and-daklatasuvir. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing